NXL (Nexalin Technology) Total Operating Expense : $7.89 Mil (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology Total Operating Expense?

Nexalin Technology's Total Operating Expense for the three months ended in Dec. 2024 was $2.90 Mil. Nexalin Technology's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was $7.89 Mil.

Nexalin Technology Total Operating Expense Historical Data

The historical data trend for Nexalin Technology's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology Total Operating Expense Chart

Nexalin Technology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Total Operating Expense

3.47

6.14

2.79

5.78

7.89

Nexalin Technology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Operating Expense	Get a 7-Day Free Trial												1.64	1.14	1.32	2.53	2.90

Nexalin Technology Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.

Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.89 Mil.

Nexalin Technology Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Nexalin Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » Total Operating Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1776 Yorktown, Suite 550, Houston, TX, USA, 77056

Website

https://www.nexalin.com

Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Executives

David Owens	director, officer: Chief Medical Officer	4545 HARRIS TRAIL NW, ATLANTA GA 30327
Marilyn Elson	10 percent owner, officer: Ms. Elson serves as CFO	32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad	director	6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White	director, officer: President/CEO	1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
Alan Kazden	director	3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser	other: Spouse
Ben Hu	director	7021 EDGERTON ROAD, NORTH ROYALTON OH 44133